Isolation and structure determination of a new lantibiotic cinnamycin B from *Actinomadura atramentaria* based on genome mining

著者	Kodani Shinya, Komaki Hisayuki, Ishimura Sho, Hemmi Hikaru, Ohnishi?Kameyama Mayumi
journal or publication title	Journal of Industrial Microbiology & Biotechnology
volume	43
number	8
page range	1159-1165
year	2016-06-02
出版者	Springer Nature
権利	(C) Society for Industrial Microbiology and Biotechnology 2016
URL	http://hdl.handle.net/10297/10284

doi: 10.1007/s10295-016-1788-9

Isolation and structure determination of a new lantibiotic cinnamycin B from

Actinomadura atramentaria

Running headline: Structural determination of cinnamycin B

Authors: Shinya Kodani^{1,2,3}, Hisayuki Komaki⁴, Sho Ishimura², Hikaru Hemmi⁵,

Mayumi Ohnishi-Kameyama⁵,

Affiliations: ¹College of Agriculture, Academic Institute, Shizuoka University, 836

Ohya, Suruga-ku, Shizuoka 422-8529 Japan; ²Graduate School of Integrated Science

and Technology, Shizuoka University, 836 Ohya, Suruga-ku, Shizuoka 422-8529 Japan;

³Graduate School of Science and Technology, Shizuoka University, 836 Ohya, Suruga-

ku, Shizuoka 422-8529 Japan; ⁴Biological Resource Center, National Institute of

Technology and Evaluation (NBRC), 2-5-8 Kazusakamatari, Kisarazu, Chiba 292-0818,

Japan; ⁵National Food Research Institute, NARO, 2-1-12 Kan-nondai, Tsukuba, Ibaraki

305-8642 Japan;

*To whom correspondence should be addressed: Shinya Kodani, College of Agriculture,

Academic Institute, Shizuoka University, 836 Ohya, Suruga-ku, Shizuoka 422-8529

Japan, Tel/Fax; +81(54)238-5008, E-mail; kodani.shinya@shizuoka.ac.jp

Abstract

New lantibiotic cinnamycin B was isolated from the extract of *Actinomadura atramentaria* NBRC 14695^T, based on genome-mining and chemical investigation. The partial structure of cinnamycin B was established by 2D NMR experiments, which indicated that cinnamycin B had same methyl lanthionine bridging pattern with cinnamycin. The reduction with NaBH₄-NiCl₂ afforded the reduced cinnamycin B, and MS/MS experiment indicated the presence of hydroxy aspartic acid in the molecule. Cinnamycin B showed an antibacterial activity against *Streptomyces antibioticus* with dosage of 5 µg at spot-on-lawn testing method. The gene cluster of cinnamycin B on the genome of *A. atramentaria* was identified and discussed in comparison with that of cinnamycin.

Keywords: *Actinomadura atramentaria* NBRC14695, lantibiotic, NMR spectrum,

MS/MS analysis

Introduction

Lantibiotics are a class of peptide antibiotics that contain thioether amino acids including lanthionine and/or methyllanthionine [26,21,5]. In addition to the thioether amino acids, lantibiotics normally possess the unsaturated amino acids including dehydroalanine and/or 2-aminoisobutyric acid. Lantibiotics are produced by a large number of gram-positive bacteria such as *Streptococcus* and *Streptomyces*. A quadrocyclic lantibiotic cinnamycin (**2**, Fig. 1) was isolated as an antibacterial compound from *Streptomyces cinnamoneus* [3,6,1]. Cinnamycin had the structure containing unique unusual amino acids such as lysinoalanine and β -hydroxy aspartic acid (HOAsp) in addition to unusual amino acids like lanthionine and methyllanthionine to form cyclic structure. The cinnamycin-related lantibiotics including ancovenin [11] and duramycins [8,7] were isolated from actinomycetes. Among the peptides, the biosynthetic cluster of cinnamycin was cloned and engineered in heterologous expression experiments [25]. The posttranslational modification system of cinnamycin was studied [19]. The genetic studies indicated that just 4 genes including *cinA*, *cinM*, *cinX*, and *cinorf7* are required for formation of cinnamycin [19]. Especially, a small protein encoded by *cinorf7* is indicated to be critical for the formation of lysinoalanine by coexpression studies in *E. coli* [19]. Among four genes, *cinX* coding protein was

indicated to be an enzyme catalyzing the hydroxylation of Asp to give HOAsp [19].

Recently, the bioactivities of duramycin and cinnamycin have been focused since they can become possible probes for phosphatidylethanolamine (PE) [10]. Duramycin and cinnamycin were indicated to bind the head group of PE with high affinity at a molar ratio of 1:1, with the dissociation constant toward PE-containing lipid membranes in the low nanomolar range [16]. The compounds like duramycin and cinnamycin which disrupt PE association with phosphatidylserine receptors necessary for entry of many enveloped viruses are a promising broad-spectrum antiviral strategy [22]. These circumstances prompted us to find new lantibiotic related to cinnamycin. Based on the genome mining approach using cinnamycin biosynthetic gene, we found new lantibiotic named cinnamycin B from *Actinomadura atramentaria* NBRC 14695^T. The structure was determined by the combination of NMR and MS analyses. Here we describe the isolation and structural determination of new lantibiotic cinnamycin B (**1**, Fig. 1) and the assignment of putative biosynthetic gene cluster of cinnamycin B.

Materials and Methods

Bacterial strains

The microorganisms (bacterial strains including *Actinomadura atramentaria* NBRC 14695^T, *Escherichia coli* NBRC 102203^T, *Serratia marcescens* NBRC102204^T,

Pseudomonas aeruginosa NBRC 12689^T, *Bacillus subtilis* subsp *subtilis* NBRC 13719^T, *Staphylococcus aureus* subsp. *aureus* NBRC 100910^T, *Micrococcus luteus* NBRC 3333^T, *Streptomyces antibioticus* NBRC 3117; Yeast strains including *Saccharomyces cerevisiae* NBRC 2376, *Schizosaccharomyces pombe* NBRC0340, *Kloeckera apiculata* NBRC 0154; fungi strains including *Aspergillus niger* NBRC 33023^T, *Aspergillus oryzae* NBRC 4290, *Mucor hiemalis* NBRC 9405^T) were obtained from the NBRC culture collection (Biological Resource Center, NITE, Japan).

Isolation of cinnamycin B

Actinomadura atramentaria NBRC 14695^T was cultured using 3L of ISP2 agar medium for 7 days at 30 °C. The aerial hyphae and spore cells on the agar surface were harvested with steel spatula. Double volume of MeOH was added to the harvested cells, followed by filtration with paper filter (Whatman No. 1, GE Healthcare Life Sciences, Little Chalfont, UK). The MeOH extract was concentrated to an aqueous residue using rotary evaporator. The aqueous residue was subjected to open column chromatography using hydrophobic resin CHP-20P (Mitsubishi Chemical, Tokyo, Japan), eluted with 10% MeOH, 60% MeOH, and 100% MeOH. The 100% MeOH fraction was subjected to HPLC purification using C8 column (4.6 × 250 mm, 5C8-MS, nacalai tesque, Kyoto, Japan) with isocratic elution from 30% MeCN

containing 0.05% trifluoroacetic acid with UV detector set at 220 nm to yield 5.3 mg of **1** (Retention time: 15.1 min).

Amino acid analysis

The amino acid content of **1** was determined by HPLC analysis of PTC-derivatized amino acids [9]. For hydrolysis, compound **1** (0.2 mg) was incubated in 100 μ L of 6N HCl at 110 $^{\circ}$ C for 16 h. Aliquot of 40 μ L of hydrolyzed sample, or aliquot of 10 μ L of amino acid mixture standard solution (Wako Pure Chemical Industries, Ltd., Osaka, Japan) was evaporated by a freeze dryer. Aliquots of 20 μ L of ethanol/water/triethylamine (2/2/1, v/v/v) were added to each sample and evaporated by a freeze dryer. For PTC-derivatization of amino acids, aliquots of 50 μ L of ethanol/water/triethylamine/phenylisocyanate (7/1/1/1, v/v/v/v) were added to each sample, and derivatization was accomplished by incubation at room temperature for 20 min. After evaporation using a freeze dryer, 1.0 ml of PTC-derivatized amino acid mobile phase A (60mM CH₃COONa aqueous solution pH 6.0/MeCN, 6:94) was added to dissolve each sample. The PTC-derivatized samples were analyzed using an HPLC system (PU980 system, JASCO, Tokyo, Japan). The conditions for HPLC analysis were following: HPLC column, Wakopak Handy-ODS (4.6 mm $\times$ 250 mm; Wako Pure Chemical Industries, Ltd.); mobile phase A (60mM CH₃COONa aqueous solution pH

6.0/MeCN, 6:94); mobile phase B (60mM CH₃COONa aqueous solution pH 6.0/MeCN, 60:40); flow rate, 1 ml/min; gradient of mobile phase B, 5% to 65% from 0 to 30 min (linear gradient); UV detector, 254 nm.

Reduction of cinnamycin B with NaBH₄-NiCl₂

Compound **1** (1.0 mg) and NiCl₂ (1.0 mg) were suspended in 1.0 mL of MeOH/H₂O(1:1). NaBH₄ (1.0 mg) was added to the mixture, followed by stirring for 1h at 50 °C. A black precipitate (Ni₂B) formed with generation of deuterium gas. After centrifugation at 14500 rpm for 1 min, supernatant was evaporated by rotary evaporator. The dried material was re-dissolved in MeOH (0.5 mL). The solution was subjected to HPLC analysis using ODS column C8 column (4.6 × 250 mm, 5C8-MS, nacalai tesque) with isocratic elution from 30% MeCN containing 0.05% trifluoroacetic acid with UV detector set at 220 nm to yield reduced cinnamycin B (Retention time: 11.2 min).

NMR experiments

An NMR sample was prepared by dissolving **1** in 500 µl of DMSO-*d*₆. 1D ¹H, ¹³C, DEPT-135, and all 2D NMR spectra were obtained on Bruker Avance800 spectrometer with quadrature detection. The 1D ¹H, ¹³C, DEPT-135 spectra were recorded at 25°C with 20 ppm for proton and 240 ppm for carbon. The following 2D ¹H-NMR spectra were

recorded at 25°C with 10 ppm or 12 ppm spectral widths in t_1 and t_2 dimensions in the phase-sensitive mode by States-TPPI method: 2D double quantum filtered correlated spectroscopy (DQF-COSY), recorded with 512 and 2048 complex points in t_1 and t_2 dimensions; 2D homonuclear total correlated spectroscopy (TOCSY) with MLEV-17 mixing sequence, recorded with mixing time of 80 ms, 256 and 2048 complex points in t_1 and t_2 dimensions; 2D nuclear Overhauser effect spectroscopy (NOESY), recorded with mixing time of 200 ms, 256 and 2048 complex points in t_1 and t_2 dimensions. Water suppression was performed using presaturation method. 2D ^1H - ^{13}C heteronuclear single quantum correlation (HSQC) and heteronuclear multiple bond connectivity (HMBC) spectra were acquired at 25 °C in the echo-antiecho mode or in the absolute mode, respectively. The ^1H - ^{13}C HSQC and HMBC spectra were recorded with 1024×512 complex points or 1024×256 complex points for 12 ppm in the ^1H dimension and 170 ppm in the ^{13}C dimension or for 10 ppm in the ^1H dimension and 170 ppm in the ^{13}C dimension, respectively, at a natural isotope abundance. 2D ^1H - ^{15}N HSQC spectrum was also recorded at 25°C with 1024×128 complex points for 12 ppm in the ^1H dimension and 50 ppm in the ^{15}N dimension in the phase-sensitive mode by States-TPPI method at a natural isotope abundance. All NMR spectra were processed using XWINNMR (Bruker). Before Fourier transformation, the shifted sinebell window function was

applied to t_1 and t_2 dimensions except for the HMBC spectrum. All ^1H and ^{13}C dimensions were referenced to DMSO- d_6 at 25°C.

MS experiments

Composition formulae of compounds were calculated from accurate mass values obtained from an electrospray ionization (ESI) Fourier-transform ion cyclotron resonance (FT-ICR) mass spectrometer (solarix XR, Bruker Daltonics) in the positive-ion mode. MS/MS spectra were recorded on a matrix-assisted laser desorption/ionization (MALDI)-time-of-flight (TOF)/TOF mass spectrometer (4800 plus TOF/TOF analyzer, AB SCIEX, CA, USA) in the positive-ion mode with an acceleration voltage of 20 kV. α -Cyano-4-hydroxycinnamic acid (Bruker Daltonics, MA, USA) was used as the matrix.

Results

By BLAST similarity search [4] using the amino acid sequence of cinnamyin (accession number, P29827.1), we found four cinnamycin analogue prepeptide genes in four actinomycetes (*Actinomadura atramentaria*, *Actinomadura oligospora*, *Streptomyces roseoverticillatus*, and *Nocardiopsis potens*, in Fig. 2). The leader peptide sequences (63 amino acids residues from N-terminus in the case of CinA, Fig. 2) that are cleaved off during modification had the conserved amino acid motif shown by underlines in Fig. 2. The structural peptide sequences were conserved and the sequence of CSXGXFTXXCDGXTK was found to be common motif for cinnamycin analogues as shown in bold letters in Fig. 2. The genetic data prompted us to perform chemical investigation on *Actinomadura atramentaria* searching for new cinnamycin analogue. As a result of preliminary culture and chemical analysis using HPLC and ESI-TOF-MS (Fig. S1), the production of new cinnamycin analogue cinnamycin B (**1**, Fig. 1) was detected in MeOH extract of culture of *A. atramentaria* NBRC 14695^T.

To obtain enough amount of **1** for structure determination, cultivation of *A. atramentaria* NBRC 14695^T was performed with 3 L of ISP2 agar media. After 7 days of cultivation, cells of spore and aerial hyphae were harvested by steel spatula. The cells were extracted with double volume of MeOH, followed by centrifugation. After

condensation using rotary evaporator, the extract was subjected to open column chromatography using hydrophobic resin CHP-20P, eluted with 10%, 60%, and 100% MeOH. The 100% MeOH fraction was repeatedly subjected to HPLC purification to afford **1**.

The molecular formula of **1** was established to be $C_{79}H_{114}N_{20}O_{25}S_3$ by the accurate mass analysis using ESI-FTCR mass spectrometry ($[M+2H]^{2+}$ at m/z 920.3792 was of $C_{79}H_{116}N_{20}O_{25}S_3$ whose calculated value was 920.3786). The molecular formula indicated that same posttranslational modification (four dehydration: $-H_2O \times 4$, one hydroxylation: $+O$) may occur during maturation of cinnamycin prepeptide (CASTCSAGPFTFVCDGTTK; molecular formula, $C_{79}H_{122}N_{20}O_{28}S_3$), compared to biosynthesis of cinnamycin. According to previous report [9], amino acid content analysis of cinnamycin B was performed and the analysis gave 2 moles each of Gly, Ala, and Phe, 1 mole each of Ser, Thr, Pro, Val at mole rate. To obtain further information on the chemical structure, NMR experiments including 1H , ^{13}C , HMQC, HMBC, DQFCOSY, TOCSY, and NOESY analyses of **1** were performed in DMSO- d_6 (Fig. S4-S10). As a result of analysis of NMR data, four partial peptide sequences (Gly16-Thr17-S-Abu18-Lys19, S-Ala1-Ala2-Ser3-S-Abu4-S-Ala5, Phe12-Val13-S-Ala14, Phe10-S-Abu11) were established by correlations of HMBC and NOESY

experiments (Fig. 3a). The bridging pairs of methyl lanthionines were established to be S-Ala1/S-Abu18, S-Ala14/S-Abu4, and S-Ala5/S-Abu11 by correlation of NOESY between β -protons of S-Ala and S-Abu (Fig. 3a). This result indicated that cinnamycin B possessed the same lanthionine bridging pattern with cinnamycin [3].

The amino acid residues of Ala7, Gly8, and Pro9 were assigned by NMR spectra, although amide protons of Ala7 and Gly8 were not observed. The connections could not be established by HMBC or NOESY experiment regarding the amino acids of Ala7, Gly8, and Pro9. Based on the amino acid sequence of biosynthetic gene of cinnamycin B prepeptide, the sequence of the amino acids was proposed to be Ala7-Gly8-Pro9. Since the methyl lanthionine bridges hamper the fragmentation analysis by MS/MS experiment, NaBH₄-NiCl₂ reduction was performed on **1**, according to the previous reports [18,15,12]. After HPLC purification, the molecular formula of the reduced cinnamycin B was established to be C₇₉H₁₁₆N₂₀O₂₅S by the accurate mass analysis using ESI-FTCR mass spectrometry ([M+2H]²⁺ at m/z 889.4146 whose calculated value was 889.4143). Reduction with NaBH₄-NiCl₂ on lanthibiotic was reported to give amino butyric acid (Abu) and Ala from methyl lanthionine [18,15,12].

The discrepancy of the molecular formula between before/after the reduction indicated that two methyl lanthionine were reduced (theoretically, loss of two sulfur:-S₂ and gain

of four hydrogen: +H₄). However, the discrepancy was loss of two sulfur (-S₂) and gain of two hydrogen (+H₂), which indicated that an unexpected dehydrogenation or incomplete reduction could occur during the reaction. The MS/MS fragmentation analysis indicated the two amino acid sequences of Ala-Ala-Ser-dehydrobutric acid (Dhb) and Val-Ala-HOAsp-Gly (Fig. 3b), indicating the presence of HOAsp in the molecule. Although two amino acids including N-Ala₆ and HOAsp₁₅ were not detected by NMR experiments, we proposed the structure of cinnamycin B to be **1** (Fig. 1), based on the chemical analyses described above and the biosynthetic prepeptide sequence.

The anti-microbial assay using spot-on-lawn method was accomplished against microorganisms (Bacterial strains including *Escherichia coli*, *Pseudomonas aeruginosa*, *Serratia marcescens*, *Bacillus subtilis*, *Staphylococcus aureus*, *Micrococcus luteus*, *Streptomyces antibioticus*; Yeast strains including *Saccharomyces cerevisiae*, *Schizosaccharomyces pombe*, *Kloeckera apiculata*; fungi strains including *Aspergillus niger*, *Aspergillus oryzae*, *Mucor hiemalis*) following a previous report [24,20].

Cinnamycin B showed antibacterial activity only against *Streptomyces antibioticus* at the dosage of 5 µg (Fig. S11).

Discussion

The cinnamycin biosynthetic gene (*cin*) cluster of *Streptomyces cinnamoneus* DSM 40005^T contains 21 open reading frames (ORFs), among which *cinA*, *cinM*, *cinX* and *cinorf7* are essential for cinnamycin synthesis. *CinT*, *cinH* and *cinY* are responsible for self-resistance, and *cinR* and *cinK* are for regulation, but the functions of the remaining twelve ORFs are unclear [25,19]. Since the draft genome sequence of *Actinomadura atramentaria* DSM 43919^T (=NBRC 14695^T) is available in public databases, we searched the biosynthetic gene cluster for cinnamycin B in the genome (Table S2, Figure 4a) and compared it with the *cin* cluster of *S. cinnamoneus* DSM 40005^T (Fig. 4b). G339_RS0112030 (WP_019631332) encodes preprocinamycin B homologous to CinA. An AYA motif, similar to AFA in CinA, is present as cleavage site between the leader sequence and the core region for cinnamycin B (Fig. 2). In cinnamycin production, the AFA sequence is predicted to be recognized by type I signal peptidase of the general secretory pathway for the explanation of the absence of cinnamycin-specific protease in the cluster [25]. In contrast, we found that a protein encoded by G339_RS0112005 has trypsin-like serine protease region, which may be responsible for the cleavage. Just next to preprocinamycin B gene, genes homologous to *cinorf7*, *cinM* and *cinX* are present and the gene organization is the same as that of the *cin* cluster (Figure 4). Therefore, we assumed that these three genes are responsible for

posttranslational modification to the precursor peptide to yield cinnamycin B in the same manner as cinammycin synthetic pathway[19]. CinM homolog (G339_RS0112025), a member of the LanM family[2], catalyzes the dehydration Thr4, Ser6, Thr11 and Thr18 in the precursor peptide and the subsequent cyclization of three Cys residues to form three methyllanthionine bridges. CinX homolog (G339_RS0112020), an α -ketoglutarate/iron(II)-dependent hydroxylase, hydroxylates Asp15 of the precursor peptide. Cinorf7 homolog (G339_RS0112035) is involved in the formation of cross-link between Lys19 and dehydroalanine6 to make a lysinoalanine bridge. Downstream of *cinX* homolog, G339_RS33385 is present and has been annotated to encode a hypothetical protein (319 aa) by RefSeq. However, we found it to encode an ABC transporter (666 aa) through the manual annotation in this study. In the *cin* cluster of *S. cinnamoneus* DSM 40005^T, the ABC transporter corresponding to this composed of two proteins of CinT (309 aa) and CinH (290 aa), which encode ATP-binding subunit and membrane permease subunit, respectively, and suggested to be involved in drug efflux and resistant. The *cin* cluster of *S. cinnamoneus* DSM 40005^T harbors *cinY* in addition to *cinT* and *cinH* for self-resistance. In contrast, cinnamycin B gene cluster does not encode *cinY* homolog, suggesting the ABC transporter encoded by correctly annotated G339_RS33385 may entirely fulfill the immunity role for lantibiotics without

CinY-like proteins. The cinnamycin B gene cluster contains two transcriptional regulatory genes, but they are not homologs of *cinR* and *cinK*, suggesting the regulatory systems of are distinct between productions of cinnamycin by *S. cinnamoneus* DSM 40005^T and cinnamycin B by *A. atramentaria* DSM 43919^T. ORFs other than the homologs of *cinA*, *cinM*, *cinX* *cinorf7* and *cinTH* in the cinnamycin B gene cluster did not show similarities to any genes in the *cin* cluster of *S. cinnamoneus* DSM 40005^T. Thus, except for these five genes, transcriptional regulatory genes and a protease gene, the others may not be essential for the production of cinnamycins.

Normally, few secondary metabolites are produced in laboratory condition compared with the numbers of biosynthetic gene clusters especially in actinomycetes. In the same manner with *A. atramentaria*, we performed chemical investigation on the other actinomycetes (*Streptomyces roseoverticillatus*, *Nocardiopsis potens*, *Actinomadura oligospora*) which had possible cinnamycin biosynthetic genes. As a result, no production of cinnamycin analogue was observed on the three actinomycetes in the condition (Data not shown).

Genome-mining approach is powerful method to find new secondary metabolites [14], especially new ribosomally synthesized peptides including lantibiotics [23], thiopeptides [13], and lasso-peptides [17]. Without usual chemical screening of many

numbers of actinomycetes (bacterial culture, extraction, and antibacterial assay), in silico screening from massive genome data can be possible to find the new peptides. In this study, just four strains were chemically screened to find a new cinnamycin analogue, indicating there was the possibility that more peptides could be found from larger numbers of bacterial genome data. We believed that this study indicated one example which proved the efficiency of genome-mining approach.

Conflict of interest

The authors disclose no conflict of interest.

Acknowledgments

This study was supported by the Japan Society for the Promotion of Science by Grants-in-aids (grant number 25350964).

References

1. Abou-Zeid AA, el-Gammal AA (1971) Influence of carbon & nitrogen sources on the production of cinnamycin by *Streptomyces cinnamomeus*. Indian J Exp Biol 9(2):274-275
2. Begley M, Cotter PD, Hill C, Ross RP (2009) Identification of a novel two-peptide lantibiotic, lichenicidin, following rational genome mining for LanM proteins. Appl Environ Microbiol 75(17):5451-5460. doi:10.1128/AEM.00730-09
3. Benedict RG, Dvorch W, Shotwell OL, Pridham TG, Lindenfelser LA (1952) Cinnamycin, an antibiotic from *Streptomyces cinnamomeus* nov. sp. Antibiot Chemother (Northfield) 2(11):591-594
4. Camacho C, Coulouris G, Avagyan V, Ma N, Papadopoulos J, Bealer K, Madden TL (2009) BLAST+: architecture and applications. BMC Bioinformatics 10:421. doi:10.1186/1471-2105-10-421
5. Chatterjee C, Paul M, Xie L, van der Donk WA (2005) Biosynthesis and mode of action of lantibiotics. Chem Rev 105(2):633-684. doi:10.1021/cr030105v
6. Dvorch W, Shotwell OL, Benedict RG, Pridham TG, Lindenfelser LA (1954) Further studies on cinnamycin, a polypeptide antibiotic. Antibiot Chemother

(Northfield) 4(11):1135-1142

7. Fredenhagen A, Fendrich G, Marki F, Marki W, Gruner J, Raschdorf F, Peter HH (1990) Duramycins B and C, two new lanthionine containing antibiotics as inhibitors of phospholipase A2. Structural revision of duramycin and cinnamycin. J Antibiot (Tokyo) 43(11):1403-1412
8. Hayashi F, Nagashima K, Terui Y, Kawamura Y, Matsumoto K, Itazaki H (1990) The structure of PA48009: the revised structure of duramycin. J Antibiot (Tokyo) 43(11):1421-1430
9. Heinrikson RL, Meredith SC (1984) Amino acid analysis by reverse-phase high-performance liquid chromatography: precolumn derivatization with phenylisothiocyanate. Anal Biochem 136(1):65-74
10. Hou S, Johnson SE, Zhao M (2015) A One-Step Staining Probe for Phosphatidylethanolamine. Chembiochem. doi:10.1002/cbic.201500127
11. Kido Y, Hamakado T, Yoshida T, Anno M, Motoki Y, Wakamiya T, Shiba T (1983) Isolation and characterization of ancovenin, a new inhibitor of angiotensin I converting enzyme, produced by actinomycetes. J Antibiot (Tokyo) 36(10):1295-1299
12. Kodani S, Lodato MA, Durrant MC, Picart F, Willey JM (2005) SapT, a

lanthionine-containing peptide involved in aerial hyphae formation in the streptomycetes. *Mol Microbiol* 58(5):1368-1380. doi:10.1111/j.1365-2958.2005.04921.x

13. Li C, Kelly WL (2010) Recent advances in thiopeptide antibiotic biosynthesis. *Nat Prod Rep* 27(2):153-164. doi:10.1039/b922434c
14. Licona-Cassani C, Cruz-Morales P, Manteca A, Barona-Gomez F, Nielsen LK, Marcellin E (2015) Systems Biology Approaches to Understand Natural Products Biosynthesis. *Front Bioeng Biotechnol* 3:199. doi:10.3389/fbioe.2015.00199
15. Lohans CT, Vederas JC (2014) Structural characterization of thioether-bridged bacteriocins. *J Antibiot (Tokyo)* 67(1):23-30. doi:10.1038/ja.2013.81
16. Machaidze G, Seelig J (2003) Specific binding of cinnamycin (Ro 09-0198) to phosphatidylethanolamine. Comparison between micellar and membrane environments. *Biochemistry* 42(43):12570-12576. doi:10.1021/bi035225b
17. Maksimov MO, Link AJ (2014) Prospecting genomes for lasso peptides. *J Ind Microbiol Biotechnol* 41(2):333-344. doi:10.1007/s10295-013-1357-4
18. Martin NI, Sprules T, Carpenter MR, Cotter PD, Hill C, Ross RP, Vederas JC (2004) Structural characterization of lacticin 3147, a two-peptide lantibiotic with

synergistic activity. *Biochemistry* 43(11):3049-3056. doi:10.1021/bi0362065

19. Okesli A, Cooper LE, Fogle EJ, van der Donk WA (2011) Nine post-translational modifications during the biosynthesis of cinnamycin. *J Am Chem Soc* 133(34):13753-13760. doi:10.1021/ja205783f
20. Pan SJ, Cheung WL, Fung HK, Floudas CA, Link AJ (2011) Computational design of the lasso peptide antibiotic microcin J25. *Protein Eng Des Sel* 24(3):275-282. doi:10.1093/protein/gzq108
21. Patton GC, van der Donk WA (2005) New developments in lantibiotic biosynthesis and mode of action. *Curr Opin Microbiol* 8(5):543-551. doi:10.1016/j.mib.2005.08.008
22. Richard AS, Zhang A, Park SJ, Farzan M, Zong M, Choe H (2015) Virion-associated phosphatidylethanolamine promotes TIM1-mediated infection by Ebola, dengue, and West Nile viruses. *Proc Natl Acad Sci U S A* 112(47):14682-14687. doi:10.1073/pnas.1508095112
23. Sandiford SK (2014) Advances in the arsenal of tools available enabling the discovery of novel lantibiotics with therapeutic potential. *Expert Opin Drug Discov* 9(3):283-297. doi:10.1517/17460441.2014.877882
24. Shi Y, Bueno A, van der Donk WA (2012) Heterologous production of the

lantibiotic Ala(0)actagardine in *Escherichia coli*. Chem Commun (Camb)

48(89):10966-10968. doi:10.1039/c2cc36336d

25. Widdick DA, Dodd HM, Barraille P, White J, Stein TH, Chater KF, Gasson MJ, Bibb MJ (2003) Cloning and engineering of the cinnamycin biosynthetic gene cluster from *Streptomyces cinnamoneus cinnamoneus* DSM 40005. Proc Natl Acad Sci U S A 100(7):4316-4321. doi:10.1073/pnas.0230516100
26. Willey JM, van der Donk WA (2007) Lantibiotics: peptides of diverse structure and function. Annu Rev Microbiol 61:477-501. doi:10.1146/annurev.micro.61.080706.093501

Figure legends

Figure 1. Structures of cinnamycin B (**1**) and cinnamycin (**2**).

Figure 2. Alignments of amino acid sequences of cinnmycin prepeptide gene analogues.

Arrow indicates cleavage site. Abbreviations, *S. cin*: *Streptomyces cinnamoneous*; *A. art*:

Actinomadura atramentaria; *S.ros*: *Streptomyces roseoverticillatus*;

N. pot: *Nocardiopsis potens*; *A. oli*: *Actinomadura oligospora*.

Figure 3. a) Key 2D NMR correlations of partial structure of **1**, b) MS/MS

fragmentation analysis on reduced **1**

Figure 4. Gere organizations of cinnamycin B biosynthetic gene cluster in

Actinomadura atramentaria (a) and cinnamycin biosynthetic gene (*cin*) cluster in

Streptomyces cinnamoneous (b).

The homologous gene pairs are shown in the same colors or patterns.

Cinnamycin B (**1**) X₁=Ala, X₂=Ser, X₃=Abu, X₄=Ala, X₅=Thr
 Cinnamycin (**2**) X₁=Arg, X₂=Gln, X₃=Ala, X₄=Phe, X₅=Asn

Figure 1. Kodani et al.

Accession number	amino acid sequence
P29827 (<i>cin</i> , <i>S. cin</i>)	MTAS-I LQQSVVDADFRAALLENFAAFGASAAALPTPVEAQDQASLDFWTKDIAATEAFACRQSCSFGPFTFVCDGNTK
WP_019631332 (<i>A. art</i>)	MSPSTILRQAAADAEFR TALL TDPVEFGVAADAVPESVEQQQESLGFWTEGVAAIDAYACASTCSAGPFTFVCDGTIK
WP_030367889 (<i>S. ros</i>)	MTAT-MLRQTVVDAAEFRAAVLADPAAFGLSATSLPAAVEDFDQESLDFWTEGAVAMNAVECTSSCSGGRFTIIICDGGTK
WP_017591584 (<i>N. pot</i>)	MTQSTILRQAAADAEFRRI LAD PSLFGISADSVPSVEQPDASLEFWTRGQGAMETVACRTSCSWGPFTIACDGSIKP
WP_026413721 (<i>A. oli</i>)	MTATSI L RHAAADAEFRSE LL ERPTDFGVT--AVFAGVEQPD AE QLGYWTEGVAAVDIYACSSSTCSFGPFTIVCDGTIKGQ

Arrow indicates cleavage site.

S.cin: *Streptomyces cinnamomeus*; *A. art*: *Actinomadura atramentaria*; *S.ros*: *Streptomyces roseovercillatus*

N. pot: *Nocardioopsis potens*; *A. oli*: *Actinomadura oligospora*.

Figure 2. Kodani et al.

Figure 3. Kodani et al.

Figure 4. Kodani et al.